Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
Roberto CairoliGianluca FurneriRoberto Di VirgilioBarbara VeggiaFelicetto FerraraPublished in: BMC health services research (2023)
Not applicable.